Filing Details

Accession Number:
0001209191-20-038242
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-22 17:29:18
Reporting Period:
2020-06-18
Accepted Time:
2020-06-22 17:29:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1000694 Novavax Inc NVAX Biological Products, (No Disgnostic Substances) (2836) 222816046
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1342823 M Gregory Glenn C/O Novavax, Inc.
21 Firstfield Road
Gaithersburg MD 20878
President, R&D No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-18 16,749 $42.20 18,588 No 4 M Direct
Common Stock Disposition 2020-06-18 16,749 $59.53 1,839 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to buy) Disposition 2020-06-18 16,749 $0.00 16,749 $42.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-07-01 No 4 M Direct
Footnotes
  1. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.32 to $59.73, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  2. The shares subject to this option grant under the Novavax, Inc. 2005 Stock Incentive Plan, as amended, vested in three equal annual installments on the first three anniversaries of the July 1, 2010 grant date.